Literature DB >> 12479369

Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.

Manny D Bacolod1, Stewart P Johnson, Francis Ali-Osman, Paul Modrich, Nancy S Bullock, O Michael Colvin, Darell D Bigner, Henry S Friedman.   

Abstract

Medulloblastoma (D-341 MED) and rhabdomyosarcoma (TE-671) cell lines, which are resistant to either 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of BCNU and O6-benzylguanine (O6-BG), were generated by serial escalation of BCNU. The activities of O6-alkylguanine-DNA alkyltransferase (AGT), glutathione-S-transferase (GST), and total glutathione (GSH) of the parental, BCNU-resistant (BR), and BCNU + O6-BG-resistant (OBR) cells were measured. No significant differences in GST activity or total GSH were seen between the parental, BR, and OBR cells of both TE-671 and D-341 MED. The AGT activities of D-341 MED (BR) and TE-671 (BR) were twice those of D-341 MED and TE-671, respectively, confirming the importance of this enzyme for BCNU resistance. The D-341 MED (OBR) cells did not exhibit any AGT activity, suggesting that another mechanism must play a role in the drug resistance. Fewer DNA interstrand cross-links (ICLs) were observed in D-341 MED (OBR) than in D-341 MED after 8 h BCNU (100-400 microM) treatment. However, the amounts of DNA ICLs observed in D-341 MED and D-341 MED (OBR) were stable after 24 h. Microarray analysis showed the increased expressions of several metallothionein genes and down-regulation of several proapoptotic genes. The AGT activity of TE-671 (OBR) was 223 fmol/mg when the cells were grown in 10 microM O6-BG and decreased to about half this value when the O6-BG concentration was increased 60 microM. The AGT cDNA of TE-671 (OBR) cells was cloned and found to contain a G-to-T transversion at codon 156, resulting in conversion of glycine to cysteine (G156C). In vitro mutagenesis has shown that the G156C AGT mutant is resistant to inactivation by O6-BG. Thus, the selection of a mutant AGT with decreased sensitivity to O6-BG is a significant contributing factor to BCNU + O6-BG resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12479369

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  11 in total

1.  Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.

Authors:  Jill A Maxwell; Stewart P Johnson; Roger E McLendon; David W Lister; Krystle S Horne; Ahmed Rasheed; Jennifer A Quinn; Francis Ali-Osman; Allan H Friedman; Paul L Modrich; Darell D Bigner; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

2.  The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.

Authors:  M D Bacolod; S M Lin; S P Johnson; N S Bullock; M Colvin; D D Bigner; H S Friedman
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

3.  Tumor-associated mutations in O⁶ -methylguanine DNA-methyltransferase (MGMT) reduce DNA repair functionality.

Authors:  Kristy L Lamb; Yanfeng Liu; Kimiko Ishiguro; Youngho Kwon; Nicolas Paquet; Alan C Sartorelli; Patrick Sung; Sara Rockwell; Joann B Sweasy
Journal:  Mol Carcinog       Date:  2012-10-12       Impact factor: 4.784

4.  Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.

Authors:  W Cai; N V Maldonado; W Cui; N Harutyunyan; L Ji; R Sposto; C P Reynolds; N Keshelava
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

5.  Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway.

Authors:  B Cui; S P Johnson; N Bullock; F Ali-Osman; D D Bigner; H S Friedman
Journal:  Mol Pharmacol       Date:  2009-03-04       Impact factor: 4.436

6.  BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line.

Authors:  Manny D Bacolod; Randy Fehdrau; Stewart P Johnson; Nancy S Bullock; Darell D Bigner; Michael Colvin; Henry S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  2008-07-17       Impact factor: 3.333

7.  Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.

Authors:  A O von Bueren; M D Bacolod; C Hagel; K Heinimann; A Fedier; U Kordes; T Pietsch; J Koster; M A Grotzer; H S Friedman; G Marra; M Kool; S Rutkowski
Journal:  Br J Cancer       Date:  2012-09-13       Impact factor: 7.640

8.  Serum metallothioneins in childhood tumours-a potential prognostic marker.

Authors:  Jarmila Kruseova; David Hynek; Vojtech Adam; Rene Kizek; Richard Prusa; Jan Hrabeta; Tomas Eckschlager
Journal:  Int J Mol Sci       Date:  2013-06-06       Impact factor: 5.923

9.  Concurrent Chemotherapy of Malignant Glioma in Rats by Using Multidrug-Loaded Biodegradable Nanofibrous Membranes.

Authors:  Yuan-Yun Tseng; Yin-Chen Huang; Tao-Chieh Yang; Shun-Tai Yang; Shou-Cheng Liu; Tzu-Min Chang; Yi-Chuan Kau; Shih-Jung Liu
Journal:  Sci Rep       Date:  2016-07-29       Impact factor: 4.379

10.  Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells.

Authors:  Bo Cui; Stewart P Johnson; Nancy Bullock; Francis Ali-Osman; Darell D Bigner; Henry S Friedman
Journal:  J Biomed Res       Date:  2010-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.